A
Anodyne Nanotech
Developing differentiated, transdermal forms of high-value drugs
About Anodyne Nanotech
Anodyne Nanotech, Inc., operating through its website theheropatch.com, is a biotechnology startup focused on revolutionizing the way medicines are delivered. The company is developing transdermal (through the skin) forms of breakthrough medicines using its patented Hero Patch technology. This technology employs hard polymeric porous microneedles on a stretchable substrate, which allows for the painless and effective delivery of milligrams of biologics (medicines derived from living organisms) directly through the skin.
Read full description
Anodyne Nanotech serves a diverse range of clients, including pharmaceutical companies, healthcare providers, and patients who require advanced drug delivery systems. The market it operates in is the biotechnology and pharmaceutical industry, specifically focusing on drug delivery technologies.
The business model of Anodyne Nanotech involves partnering with pharmaceutical companies to integrate its Hero Patch technology into their drug delivery systems. By doing so, the company helps these partners enhance the efficacy and patient compliance of their treatments. Anodyne makes money through licensing agreements, partnerships, and potentially direct sales of its Hero Patch technology to pharmaceutical companies.
The Hero Patch aims to address common issues associated with traditional drug delivery methods such as pills, topicals, and injections. These traditional methods often face challenges like poor patient compliance, variable absorption rates, and discomfort. By offering a painless and efficient alternative, Anodyne Nanotech is positioned to unlock the full potential of therapeutics, helping more patients around the world achieve better clinical outcomes.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Boston, United States
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 70.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Anodyne Nanotech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | May 2026 | $13M | $50M | Undisclosed | ↗ |
| SEED✓Equity / VC | May 2023 | $2.3M | $21M | Big Pi Ventures · Velocity Partners | ↗ |
Growth signals
Latest recorded traffic for Anodyne Nanotech is 4.3K monthly website visits, up 465.8% over the last three months. Anodyne Nanotech's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Velocity Partners Venture Capital
Big Pi Ventures
Velocity Partners
Relativity Healthcare Partners
Other known investors3 additional known investors
Tufts University- BGBantam Group
Endeavor Greece
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anodyne Nanotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anodyne Nanotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.